Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a sequential Phase I and IIa study to identify the maximum tolerated dose and to
evaluate safety, tolerability, toxicity, pharmacokinetics and pharmacodynamics of the oral
sphingosine kinase inhibitor ABC294640 specifically in patients with diffuse large B-cell
lymphoma (DLBCL), including virus-associated (e.g., KSHV- or EBV-associated) DLBCL or Kaposi
Sarcoma (KS) after failure of or intolerance to initial standard therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
RedHill Biopharma Limited
Collaborators:
Apogee Biotechnology Corporation Louisiana State University Health Sciences Center in New Orleans